News | EP Mapping and Imaging Systems | October 27, 2016

Acutus Medical Announces First Patient Procedure in UNCOVER-AF Atrial Fibrillation Trial

European and Canadian clinical study evaluates AcQMap high-resolution imaging and mapping system

Acutus Medical, AcQMap High Resolution Imaging and Mapping System, atrial fibrillation, UNCOVER-AF trial, first procedure

October 27, 2016 — Acutus Medical announced the completion of the first patient procedure in the “Utilizing Novel Dipole Density Capabilities to Objectively Visualize the Etiology of Rhythms in Atrial Fibrillation” (UNCOVER-AF) clinical study. The study will evaluate the incidence of device and procedure-related safety, effectiveness and efficiency using the AcQMap High Resolution Imaging and Mapping System to guide ablation in persistent atrial fibrillation (AF) patients.

Acutus Medical received CE Mark approval for the AcQMap System and AcQMap Catheter in May 2016. Patients are currently being enrolled in the UNCOVER-AF clinical study at electrophysiology (EP) centers of excellence throughout Europe and Canada. The first procedure was successfully completed by Andrew Grace, M.D., Ph.D. and Sharad Agarwal, M.D., at Papworth Hospital in Cambridge, United Kingdom.

“The AcQMap System ushers in a new standard of care allowing EPs who until now, have never been able to fully visualize all the electrical mechanisms combined with the functional mechanism of AF,” said Grace. “Being able to truly see each heart beat in real-time, with CT [computed tomography]-quality imaging and full-chamber electrical-conduction maps has the potential to more accurately inform treatment decisions and improve patient outcomes.”

Persistent AF is a complex, heterogeneous, patient-specific arrhythmia with limited treatment options that consist of oral medications, electric shocks to convert the heart rhythm and empiric ablation strategies. Outcomes, regardless of treatment options, have been disappointing. The AcQMap System combines a real-time CT quality anatomy with an ability to map the electrical conduction of each heartbeat to precisely visualize electric sources across the entire chamber thus enabling the pinpointing of sites crucial for driving and maintaining AF. Following guided treatment, the next heartbeat can be remapped in seconds to confirm successful ablation and define additional treatment, if needed. This progressive treatment strategy of mapping, ablating and remapping to systematically break down the complexity of the AF frequently leads to spontaneous termination with conversion to sinus rhythm.

Early clinical results using the AcQMap System have demonstrated accurate left atrial reconstruction when compared with CT/magnetic resonance imaging (MRI) and dipole density mapping offering a significantly higher resolution than voltage-based mapping.

The AcQMap High Resolution Imaging and Mapping System is not available for sale in the United States.

For more information: www.acutusmedical.com

Related Content

The study used cadaver hearts that were images with contrast enhanced MRI and the images used to create a 3-D computation model of the electrical activation in the heart and how it was influenced by adenosine and ablation. Find more images in the original article

News | Atrial Fibrillation | October 08, 2020
October 8, 2020 – People who suffer from persistent atrial fibrillation in the heart may find relief from a new treat
The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

News | Atrial Fibrillation | August 04, 2020
August 4, 2020 — Abbott announced the first enrollments in the TactiFlex PAF  investigational device exemption (IDE)
PREDICT-AF trial showed first time there is extensive extracellular matrix remodeling. #HRS2020 #Heartrhythm2020. Marilyn Fornell
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Structural changes of the atrium may occur long before the onset of atrial fibrillation (AF), and the
Results of the Atrial Fibrosis Predicts Recurrent Stroke Or New Atrial Fibrillation In Patients With Embolic Stroke Of Undetermined Source - A Multi-Center Study at HRS 2020. #HRS2020 #Heartrhythm2020,
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Atrial disease has been implicated in embolic stroke of undetermined source (ESUS) and a late-breaking
Contact Force Sensing Catheter Improved Outcomes in Persistent Atrial Fibrillation Ablation. #HRS2020 #heartrhythm2020
News | Atrial Fibrillation | May 13, 2020
May 13, 2020 — The PRECEPT study testing the use of the Biosense Webster Thermocool Smarttouch SF Catheter for the tr
The Swiss-AF study shows High Incidence Of Silent Brain Infarcts Found in Anticoagulated Atrial Fibrillation Patients. #Heartrhythm2020 #HRS20 #HRS2020
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 – A new clinical study found that patients with...
PINNACLE FLX Study of New Watchman FLX LAA Occluder Meets Safety and Efficacy Endpoints. #Heartrhythm2020 #HRS20 #HRS2020
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 — Positive 12-month results were announced today from the...
The first-in-human results show positive results for Medtronic's pulsed field ablation in safety and efficiency. #Heartrhythm2020 #HRS2020 #HRS20
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 — New clinical trial reveals the first-in-human results for paroxysmal or persistent atrial fibrillation
POPULAR TAVR trial Shows Oral Anticoagulants Alone in atrial fibrillation  (AF) Patients Reduces Bleeding Post TAVR, transcatheter aortic valve replacement. #ACC20 #ACC2020
News | Atrial Fibrillation | March 29, 2020
March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing transcath